相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm
Jonathan R. Lambert et al.
BLOOD (2009)
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele
Paola Guglielmelli et al.
BLOOD (2009)
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course
Constantine S. Tam et al.
BLOOD (2009)
The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan
Tomonori Hidaka et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Karyotype complements the International Prognostic Scoring System for primary myelofibrosis
Kebede Hussein et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera
D. Olcaydu et al.
LEUKEMIA (2009)
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients
A. Pardanani et al.
LEUKEMIA (2009)
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates
A. Tefferi et al.
LEUKEMIA (2009)
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
A. Tefferi et al.
LEUKEMIA (2009)
Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML
A. Tefferi et al.
LEUKEMIA (2009)
A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms
Damla Olcaydu et al.
NATURE GENETICS (2009)
A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms
Outi Kilpivaara et al.
NATURE GENETICS (2009)
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms
Amy V. Jones et al.
NATURE GENETICS (2009)
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice
Ralph Tiedt et al.
BLOOD (2008)
TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients
T. L. Lasho et al.
LEUKEMIA (2008)
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
A. Tefferi et al.
LEUKEMIA (2008)
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms:: a critical reappraisal
A. M. Vannucchi et al.
LEUKEMIA (2008)
JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science
O. Kilpivaara et al.
LEUKEMIA (2008)
Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders
Animesh Pardanani et al.
BLOOD (2008)
Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F
K. Shide et al.
LEUKEMIA (2008)
JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis
Annette H. Schmitt-Graeff et al.
HAEMATOLOGICA (2007)
Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera
A. Pardanani et al.
LEUKEMIA (2007)
Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes
Animesh Pardanani et al.
STEM CELLS (2007)
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations
A. Pardanani et al.
LEUKEMIA (2007)
Expression of the JAK2 V617F mutation is not found in de novo AML and MDS but is detected in MDS-derived leukemia of megakaryoblastic nature
K. Nishii et al.
LEUKEMIA (2007)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Concurrent MPL515 and JAK2V617F mutations in myelofibrosis:: chronology of clonal emergence and changes in mutant allele burden over time
Terra L. Lasho et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients
Animesh D. Pardanani et al.
BLOOD (2006)
Mutation of JAK2 in the myeloproliferative disorders:: timing, clonality studies, cytogenetic associations, and role in leukemic transformation
Peter J. Campbell et al.
BLOOD (2006)
Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia
Linda M. Scott et al.
BLOOD (2006)
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders
Robert Kralovics et al.
BLOOD (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia:: lineage specificity and clinical correlates
A Tefferi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders
LM Scott et al.
BLOOD (2005)
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both atypical myeloproliferative disorders and myelodysplastic syndromes
DP Steensma et al.
BLOOD (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The World Health Organization (WHO) classification of the myeloid neoplasms
JW Vardiman et al.
BLOOD (2002)
分享论文
